Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Srinivasu Pothukanuri

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Organic Letters|May 8, 2007
A highly efficient azide-based protecting group for amines and alcoholsSrinivasu Pothukanuri, Nicolas Winssinger
Proceedings of the National Academy of Sciences of the United States of America|February 11, 2009
Enhanced exercise capacity in mice with severe heart failure treated with an allosteric effector of hemoglobin, myo-inositol trispyrophosphateAndreia Biolo, Ruth Greferath, Deborah A Siwik, et al.
ACS Medicinal Chemistry Letters|February 19, 2021
Virtual Screening Approach to Identifying a Novel and Tractable Series of <i>Pseudomonas aeruginosa</i> Elastase InhibitorsSimon Leiris, David T Davies, Nicolas Sprynski, et al.
Journal of Medicinal Chemistry|December 11, 2020
Discovery of <b>ANT3310</b>, a Novel Broad-Spectrum Serine β-Lactamase Inhibitor of the Diazabicyclooctane Class, Which Strongly Potentiates Meropenem Activity against Carbapenem-Resistant Enterobacterales and <i>Acinetobacter baumannii</i>David T Davies, Simon Leiris, Magdalena Zalacain, et al.
ACS Infectious Diseases|August 14, 2020
ANT2681: SAR Studies Leading to the Identification of a Metallo-β-lactamase Inhibitor with Potential for Clinical Use in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing <i>Enterobacteriaceae</i>David T Davies, Simon Leiris, Nicolas Sprynski, et al.
ACS Infectious Diseases|November 15, 2018
SAR Studies Leading to the Identification of a Novel Series of Metallo-β-lactamase Inhibitors for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections That Display Efficacy in an Animal Infection ModelSimon Leiris, Alicia Coelho, Jérôme Castandet, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Organic Letters|May 8, 2007
A highly efficient azide-based protecting group for amines and alcoholsSrinivasu Pothukanuri, Nicolas Winssinger
Proceedings of the National Academy of Sciences of the United States of America|February 11, 2009
Enhanced exercise capacity in mice with severe heart failure treated with an allosteric effector of hemoglobin, myo-inositol trispyrophosphateAndreia Biolo, Ruth Greferath, Deborah A Siwik, et al.
ACS Medicinal Chemistry Letters|February 19, 2021
Virtual Screening Approach to Identifying a Novel and Tractable Series of <i>Pseudomonas aeruginosa</i> Elastase InhibitorsSimon Leiris, David T Davies, Nicolas Sprynski, et al.
Journal of Medicinal Chemistry|December 11, 2020
Discovery of <b>ANT3310</b>, a Novel Broad-Spectrum Serine β-Lactamase Inhibitor of the Diazabicyclooctane Class, Which Strongly Potentiates Meropenem Activity against Carbapenem-Resistant Enterobacterales and <i>Acinetobacter baumannii</i>David T Davies, Simon Leiris, Magdalena Zalacain, et al.
ACS Infectious Diseases|August 14, 2020
ANT2681: SAR Studies Leading to the Identification of a Metallo-β-lactamase Inhibitor with Potential for Clinical Use in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing <i>Enterobacteriaceae</i>David T Davies, Simon Leiris, Nicolas Sprynski, et al.
ACS Infectious Diseases|November 15, 2018
SAR Studies Leading to the Identification of a Novel Series of Metallo-β-lactamase Inhibitors for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections That Display Efficacy in an Animal Infection ModelSimon Leiris, Alicia Coelho, Jérôme Castandet, et al.
Pageof 1